US · PPBT
Purple Biotech Ltd.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Rehovot 7670104
- Website
- purple-biotech.com
Price · as of 2024-12-31
$4.20
Market cap 6.05K
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $162.94 | +3,779.52% |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | $6,340.00 | ||||
| 2016 | $4,073.40 | ||||
| 2017 | $5,538.00 | ||||
| 2018 | $2,400.00 | $1,840.34 | $0.00 | $0.00 | $0.00 |
| 2019 | $1,149.00 | $4,662.16 | $0.00 | $0.00 | $0.00 |
| 2020 | $970.00 | $628.52 | $61.46 | $0.00 | $0.00 |
| 2021 | $534.00 | $231.70 | |||
| 2022 | $414.00 | ||||
| 2023 | $164.20 | $5.48 | $27.71 | ||
| 2024 | $28.10 | $162.94 |
AI valuation
Our deep-learning model estimates Purple Biotech Ltd.'s (PPBT) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $162.94
- Current price
- $4.20
- AI upside
- +3,779.52%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| PPBT | Purple Biotech Ltd. | $4.20 | 6.05K | +3,780% | — | — | — | -9.98 | 2.21 | — | -9.12 | -0.37 | 14.48 | 0.00% | — | — | -21.71% | -50.41% | -17.90% | 0.01 | -24.62 | 2.23 | 2.21 | 1.02 | 266250.00% | -10000.00% | -2791.00% | -19.77% | -3.60 | -65.81% | 0.00% | 0.00% | 0.00% | -5.84 | -4.48 | — | 4.27 |
| AKTX | Akari Therapeutics, Plc | $0.24 | 4.22K | — | — | — | — | 0.00 | 0.00 | — | -0.03 | 0.00 | 0.00 | 0.00% | — | — | -179.92% | -230.05% | -72.08% | 0.15 | 88.70 | 0.15 | 0.14 | -0.03 | 73000.00% | — | -2361.00% | -113611.27% | -0.63 | -133.42% | 0.00% | 0.00% | 0.00% | -0.03 | -0.05 | — | -8.66 |
| CDT | CDT Equity Inc. | $0.69 | 936.98K | — | +2,355% | +4,622% | — | 0.11 | 0.02 | 0.01 | 3.22 | — | -0.15 | 37.98% | 11.63% | 8.75% | 37.77% | 28.00% | 13.64% | 1.09 | -6.81 | 1.93 | 1.22 | 3.14 | -12879.00% | — | -234691.00% | 845.61% | 0.51 | 19.40% | 30.80% | 3.40% | 30.80% | 3.22 | 4.65 | 0.37 | 1.88 |
| DRMA | Dermata Therapeutics, Inc… | $1.20 | 817.87K | — | — | — | — | -0.15 | 1.19 | — | 0.11 | — | 1.19 | 0.00% | — | — | -310.44% | 932.57% | -213.46% | 0.00 | — | 1.79 | 1.60 | 0.26 | -7991.00% | — | 7418.00% | -602.98% | -5.66 | 831.94% | 0.00% | 0.00% | 0.04% | 0.10 | 0.12 | — | -36.61 |
| MSPR | MSP Recovery, Inc. | $0.04 | 537.2K | +14,182% | +17,977% | — | — | -0.01 | 0.14 | 0.76 | -1.22 | -0.01 | -0.01 | 47.36% | -6982.79% | -1975.45% | -834.83% | -139.81% | -61.30% | 7.90 | -3.03 | 0.01 | 0.01 | -1.20 | 12779.00% | 13685.00% | -6014.00% | -119.26% | -0.01 | -1.83% | 0.00% | 0.00% | 0.00% | -0.62 | -47.84 | 43.63 | -3.28 |
| PBM | Psyence Biomedical Ltd. | $2.54 | 48.31K | — | — | — | — | 121.05 | 18.22 | — | 113.47 | — | 18.22 | 0.00% | — | — | -47.61% | 1045.66% | 23.95% | 0.00 | -395.15 | 11.04 | 10.55 | -5.98 | -12268.00% | — | 2687.00% | -3.06% | -6.28 | 1068.81% | 0.00% | 0.00% | 12.94% | -31.76 | -31.07 | — | 112.16 |
| REVB | Revelation Biosciences, I… | $1.32 | 1.95M | — | — | — | — | 0.00 | 0.00 | — | 0.67 | — | 0.00 | 0.00% | — | — | -201.08% | 1657.76% | -153.82% | 0.08 | — | 5.41 | 5.36 | 0.67 | -7268.00% | — | 4498931.00% | -103262.37% | -4.14 | 1511.33% | 74316.81% | -66.80% | 198525.74% | 1.10 | 1.20 | — | -7.64 |
About Purple Biotech Ltd.
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
- CEO
- Gil Efron
- Employees
- 9
- Beta
- -0.72
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $4.20) − 1 = — (DCF, example).